Core Viewpoint - Bank of America Securities reports that China Resources Pharmaceutical (03320) had a lackluster performance in the first half of the year, with a revenue growth of 2.5% and a gross margin of 16.3%, which remained relatively stable. The attributable net profit decreased by 20.3% due to impairment losses and an increase in non-controlling interests [1] Revenue and Profit Forecast - Following the mid-term performance, Bank of America Securities has lowered the revenue forecasts for China Resources Pharmaceutical for 2025, 2026, and 2027 by 3%, 3%, and 4% respectively. The earnings per share forecast has also been reduced by approximately 9% [1] Target Price Adjustment - The target price for China Resources Pharmaceutical has been adjusted from HKD 6.2 to HKD 5.7 based on discounted cash flow analysis [1] Gross Margin Outlook - Due to the increased contribution from high-margin pharmaceutical business, the gross margin forecasts for 2025, 2026, and 2027 have been raised by 0.3, 0.3, and 0.4 percentage points respectively [1] Investment Rating - Despite the adjustments, Bank of America Securities maintains a "Buy" rating, citing the company's rich portfolio of traditional Chinese medicine products, leading position in the distribution industry, and strong acquisition capabilities [1]

Investment Rating - The investment rating for the company is "Buy" [9][16] Core Views - The company's performance in H1 2025 met expectations, with a revenue of 81.11 billion yuan, representing a 5.10% increase year-on-year, and a net profit attributable to shareholders of 1.446 billion yuan, up 19.70% [3][4] - The growth in net profit was primarily driven by steady growth in pharmaceutical distribution revenue and rapid growth in emerging business segments such as pharmaceutical manufacturing and digital logistics, which saw revenue increases of 10.77% and 24.66% respectively [3][6] - The company successfully completed the issuance and listing of public REITs for pharmaceutical warehousing and logistics infrastructure, contributing an additional 438 million yuan to net profit [3][8] - The company is focusing on a digital transformation strategy, with significant investments in AI applications across various business scenarios, enhancing operational efficiency [8] Financial Performance - In H1 2025, the gross profit margin was 7.56%, a decrease of 0.35 percentage points, while the net profit margin increased by 0.22 percentage points to 1.78% [4] - The core pharmaceutical distribution business achieved sales revenue of 67.634 billion yuan, a year-on-year increase of 6.04% [6][13] - The company anticipates revenue growth for 2025-2027 to be 164.05 billion yuan, 177.33 billion yuan, and 191.63 billion yuan respectively, with net profits projected at 2.672 billion yuan, 2.899 billion yuan, and 3.209 billion yuan [9][11] Strategic Initiatives - The company is implementing a "Three New and Two Transformations" strategy, focusing on new products, new retail, new healthcare, and digitalization, with significant investments in talent and operational capabilities [5][8] - The number of franchise stores for the "Good Pharmacist" retail business reached 31,535, with sales to franchise stores amounting to 3.418 billion yuan, a year-on-year increase of 41.30% [6][8]

Core Viewpoint - CICC maintains an "outperform" rating for China National Pharmaceutical Group (01099) with a target price of HKD 24.7, indicating a potential upside of 27.2% based on projected earnings multiples for 2025 and 2026 [2] Financial Performance - For the first half of 2025, the company reported revenue of RMB 286.04 billion, a decrease of 2.95% year-on-year, and a net profit of RMB 3.466 billion, down 6.43% year-on-year, with earnings per share of RMB 1.11, aligning with CICC's expectations [2] - The net profit forecasts for 2025 and 2026 are RMB 7.475 billion and RMB 7.926 billion, respectively, both reflecting a year-on-year growth of 6.0% [2] Business Segments - **Pharmaceutical Distribution**: Revenue for pharmaceutical distribution in 1H25 was RMB 218.53 billion, down 3.52% year-on-year, with an operating profit margin of 2.58%, a decrease of 0.17 percentage points due to ongoing industry challenges [3] - **Medical Device Distribution**: Revenue for medical device distribution was RMB 57.05 billion, down 2.46% year-on-year, with an operating profit margin of 1.92%, a decline of 0.33 percentage points, impacted by price reductions from centralized procurement [3] - **Retail Pharmacy**: Retail revenue increased by 3.65% year-on-year to RMB 17.16 billion, with an operating profit margin of 2.68%, up 1.13 percentage points, benefiting from revenue growth and cost reduction strategies [4] Operational Metrics - The overall gross margin for 1H25 was 7.11%, down 0.33 percentage points, primarily due to a slight decrease in the proportion of high-margin businesses [5] - The sales expense ratio was 2.74%, down 0.13 percentage points, while the management expense ratio was 1.28%, down 0.05 percentage points, and the financial expense ratio was 0.35%, down 0.02 percentage points [5] Strategic Outlook - The company aims to strengthen its market leadership through differentiated regional business strategies and optimization of its business structure [3] - The dual-brand strategy focusing on professional pharmacies and Guoda pharmacies is expected to drive high-quality growth [4]

Core Viewpoint - The report from CICC maintains the net profit forecast for China National Pharmaceutical Group (01099) at RMB 7.475 billion and RMB 7.926 billion for 2025 and 2026 respectively, reflecting a year-on-year growth of 6.0% for both years [1] Group 1: Financial Performance - For the first half of 2025, the company reported operating revenue of RMB 286.043 billion, a decrease of 2.95% year-on-year, and a net profit attributable to shareholders of RMB 3.466 billion, down 6.43% year-on-year, resulting in earnings per share of RMB 1.11, which aligns with CICC's expectations [1] - The company's pharmaceutical distribution revenue for 1H25 was RMB 218.527 billion, a decline of 3.52% year-on-year, primarily due to the ongoing expansion of centralized procurement and national negotiations [2] - The medical device distribution revenue for 1H25 was RMB 57.053 billion, down 2.46% year-on-year, influenced by proactive business governance strategies and price reductions in centralized procurement products [2] Group 2: Profitability and Margins - The overall gross margin for the first half of 2025 was 7.11%, a decrease of 0.33 percentage points year-on-year, mainly due to a slight decline in the proportion of high-margin businesses [4] - The operating profit margin for the pharmaceutical retail business increased by 1.13 percentage points to 2.68% in 1H25, benefiting from revenue growth, network optimization strategies, and significant cost reductions [3] Group 3: Business Strategy and Outlook - The company aims to consolidate its leading position in the industry by advancing a differentiated regional business development strategy and accelerating business structure optimization [2] - The company is expected to achieve high-quality growth through the continuous deepening of its "dual-brand" strategy involving professional pharmacies and Guoda pharmacies [3]

Summary of Key Points Core Viewpoint - The company has renewed its product/service mutual supply framework agreement with Sinopharm Holdings, extending the agreement from January 1, 2026, to December 31, 2028, to support ongoing business needs [1][2]. Group Overview - The mutual supply framework agreement is essential for the company's operations, which span pharmaceutical manufacturing, medical devices, and healthcare services, creating a necessary and ongoing business relationship with Sinopharm Holdings [2][4]. Financial Data - The actual transactions between the company and Sinopharm Holdings for the years 2023, 2024, and the first half of 2025 are as follows: - Sales of raw materials or goods: 642,908,000 RMB in 2023, 557,908,000 RMB in 2024, and 292,003,000 RMB in the first half of 2025 - Purchases of raw materials or goods: 35,794,000 RMB in 2023, 45,187,000 RMB in 2024, and 21,991,000 RMB in the first half of 2025 - Provision of services: 93,000 RMB in 2023, 49,000 RMB in 2024, and 4,000 RMB in the first half of 2025 - Acceptance of services: 427,000 RMB in 2023, 179,000 RMB in 2024, and 121,000 RMB in the first half of 2025 [3][4]. Expected Transaction Limits - The expected transaction limits under the new framework agreement are as follows: - Sales of raw materials or goods: 1,100,000,000 RMB for 2026, 1,300,000,000 RMB for 2027, and 1,500,000,000 RMB for 2028 - Purchases of raw materials or goods: 80,000,000 RMB for 2026, 100,000,000 RMB for 2027, and 120,000,000 RMB for 2028 - Provision of services: 100,000 RMB for 2026, 120,000 RMB for 2027, and 150,000 RMB for 2028 - Acceptance of services: 2,000,000 RMB for 2026, 2,500,000 RMB for 2027, and 3,000,000 RMB for 2028 [4][5]. Approval Process - The renewal of the framework agreement requires approval from the company's shareholders after being reviewed and approved by the board of directors, excluding related directors [5][9].

Core Insights - The company reported total revenue of RMB 131.8668 billion, representing a year-on-year growth of 2.5% [1] - The highest revenue contribution came from pharmaceutical distribution at 79.2%, followed by pharmaceutical manufacturing at 16.6% and retail pharmacy at 4.2% [1] Financial Performance - The company's gross profit amounted to RMB 21.5096 billion, with a year-on-year increase of 2.8%, resulting in an overall gross margin of 16.3% [1] - Net profit was reported at RMB 5.0536 billion, reflecting a decline of 8.8% year-on-year; profit attributable to shareholders decreased by 20.3% to RMB 2.0773 billion [1] - Excluding one-off items, net profit and profit attributable to shareholders saw slight declines of 1.3% and 4.7% respectively [1] - Basic earnings per share were RMB 0.33, and the board declared an interim dividend of RMB 0.072 per share [1]

Core Insights - China Resources Pharmaceutical (03320) reported a mid-year performance for 2025, achieving revenue of RMB 131.867 billion, a year-on-year increase of 2.54% [1] - The company's profit attributable to equity shareholders was RMB 2.077 billion, a decrease of 20.25% year-on-year, with earnings per share at RMB 0.33 and an interim dividend proposed at RMB 0.072 per share [1] - The gross profit for the reporting period was RMB 21.5096 billion, up 2.8% from RMB 20.934 billion in the same period last year, maintaining a gross margin of 16.3% [1] Revenue Breakdown - The revenue contributions from the three main business segments were 16.6% from pharmaceuticals, 79.2% from medical distribution, and 4.2% from retail and other operations [1] - The company has a total of 83 production bases and 561 production lines, producing 944 products, with 555 products included in the national medical insurance catalog and 235 products in the essential drug list [1] Profitability Metrics - Excluding the impact of impairment and other one-off items, the net profit for the reporting period saw a slight decline of 1.3%, while the profit attributable to the company's owners decreased by 4.7% year-on-year [1]

Core Viewpoint - China Resources Pharmaceutical (03320) reported a revenue of RMB 131.867 billion for the first half of 2025, representing a year-on-year increase of 2.54% [1] Financial Performance - The profit attributable to equity shareholders was RMB 2.077 billion, a decrease of 20.25% year-on-year [1] - Earnings per share stood at RMB 0.33, with an interim dividend proposed at RMB 0.072 per share [1] - Gross profit for the period was RMB 21.5096 billion, up 2.8% from RMB 20.934 billion in the same period last year [1] - The overall gross margin remained stable at 16.3%, unchanged from the first half of 2024 [1] - Excluding impairment losses from associates and other one-off items, net profit decreased slightly by 1.3% year-on-year, while profit attributable to the company's owners fell by 4.7% [1] Business Segmentation - Revenue contributions from the three main business segments were as follows: Pharmaceuticals at 16.6%, Medical Distribution at 79.2%, and Retail Pharmacy and Others at 4.2% [1] - As of the end of the reporting period, the company operated 83 production bases and 561 production lines, producing 944 products, of which 555 are included in the National Medical Insurance Catalogue and 235 in the Essential Drug List [1]

报告期内，集团制药业务实现分部收益人民币248.083亿元，同比增长4.3%，中药、生物药、营养保健 品及其他业务板块收入均实现增长。制药业务毛利率为59.3%，较上年同期略下降0.8个百分点。 报告期内，集团医药分销业务实现分部收益人民币1083.297亿元，同比增长2.3%。分销业务毛利率为 5.9%，较上年同期持平。 报告期内，集团医药零售业务录得收益人民币55.146亿元，同比增长11.4%，主要因高值药品直送(DTP) 业务收入增速较快。报告期内，集团的DTP业务实现收益约人民币37.6亿元，同比增长约14.1%。零售 业务毛利率为6.1%，较上年同期下降0.4个百分点，主要因为毛利率水平较低的DTP业务收入比重增 加。 格隆汇8月26日丨华润医药(03320.HK)公布中期业绩，集团录得总收益达人民币1318.668亿元，较上年 同期增长2.5%。2025年上半年制药、医药分销、药品零售及其他三个主要业务分部的收益占比分别为 16.6%、79.2%以及4.2%。 报告期内，集团实现毛利人民币215.096亿元，较上年同期增长2.8%。整体毛利率为16.3%，与2024年上 半年的毛利率持平。集团实 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確性或完整性 亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容而產生或因倚賴該等內容而引致 之任何損失承擔任何責任。 中國，上海 2025 年 8 月 25 日 於本公告日期，執行董事為連萬勇先生及孫京林先生；非執行董事為趙炳祥先生、陳啟宇先生、祖敬先 生、邢永剛先生、陳玉卿先生、文德鏞先生及馮蓉麗女士；獨立非執行董事為李培育先生、吳德龍先生、 俞衛鋒先生、石晟昊先生及陳威如先生。 * 本公司以其中文名稱及英文名稱「 Sinopharm Group Co. Ltd. 」根據香港公司條例註冊為非香港公司。 海外監管公告 国药控股股份有限公司 本公告乃根據香港聯合交易所有限公司證券上市規則第 13.10B 條作出。 公司债券中期报告 以下公告的中文原稿將由國藥控股股份有限公司於 2025 年 8 月 25 日於上海證券交易所網站 (http://www.sse.com.cn)發佈，僅供參閲。 承董事會命 國藥控股股份有限公司 董事長 趙炳祥 （2025 年） 二〇二五年八月 0 国药控股股份有限公司公司债券中期报告（202 ...